The Siemens-backed cancer treatment company, which has raised $195m in funding, will look to raise up to $69m when it floats on Nasdaq.

Poxel, which is also backed by Bpifrance, will fund clinical trials for two of its drug candidates with the proceeds.

Genomic Health-backed Invitae will offer 6.35 million shares priced at $16, raising $101.6m.

Intel-backed transplant surveillance technology company CareDx has raised $40m in its initial public offering.

The Hearst-backed social media tools developer has raised $250m to date, but could wait another two years before looking to go public.

Genomic Health-backed Invitae, which is developing a new genetic testing system, would raise more than $80m if it floats at the top of its range.

The pharmaceutical company, which is developing treatments for retinal conditions, is set to float above its range.

The Kraft-backed biotechnology company, which is developing treatments for neuromuscular disorders, has gone public just five months after a $40m series A round.

Microneedle patch developer Zosano secured the cash from strategic partner Eli Lilly concurrently to a $47.5m initial public offering.

The corporate-backed online content management company will float above its range today, after raising nearly $600m in venture capital.